정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2361 | Active, not recruiting | A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adolescents | Healthy | Biological: Ad26.COV2.S Other: Placebo |
Phase 2 | Janssen Vaccines & Prevention B.V. | INDUSTRY | 635 | All | 12 Years | Charite Research Organisation GmbH, Berlin, Germany CTC North GmbH & Co. KG, Am Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany Universitaetsmedizin Rostock, Rostock, Germany PRA Health Sciences, Groningen, Netherlands Centre for Human Drug Research, Leiden, Netherlands UMCU, Utrecht, Netherlands Hosp. Univ. de La Princesa, Madrid, Spain Hosp. Univ. La Paz, Madrid, Spain Hosp. Univ. Marques de Valdecilla, Santander, Spain Bristol Royal Hospital for Children, Bristol, United Kingdom Alder Hey Hospital, Liverpool, United Kingdom St George's, University of London, London, United Kingdom Royal Manchester Children's Hospital, Manchester, United Kingdom University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom |
| 2360 | Recruiting | A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID) | Covid19 | Biological: Ampion Other: Placebo |
Phase 1 | Ampio Pharmaceuticals. Inc. | INDUSTRY | 30 | All | 18 Years | Ampio Pharmaceuticals, Englewood, Colorado, United States |
| 2359 | Recruiting | A Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19 | Covid19 | Drug: OPN-019 | Phase 1 | Optinose US Inc. | INDUSTRY | 30 | All | 18 Years | Fundacion Santos y de la Garza Evia, I.B.P, Monterrey, N.l., Mexico |
| 2358 | Completed | A Study to Evaluate Clazakizumab in Patients With Life-threatening COVID-19 Infection | Respiratory Failure | Drug: Clazakizumab Drug: Placebo |
Phase 2 | Ayan Sen | OTHER | 1 | All | 18 Years | Mayo Clinic in Arizona, Phoenix, Arizona, United States |
| 2357 | Not yet recruiting | A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive | Healthy | Biological: Ad26.COV2.S Other: Placebo |
Phase 3 | Janssen Vaccines & Prevention B.V. | INDUSTRY | 4350 | All | 12 Years ~ 17 Years | CIPREC, Buenos Aires, Argentina Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Buenos Aires, Argentina CEMEDIC, Buenos Aires, Argentina Hospital Pedro de Elizalde, City of Buenos Aires, Argentina Clinical Trials Division-Stamboulian Servicios de Salud, Ciudad Autonoma Buenos Aires, Argentina Centro Medico Barrio Parque. Swiss Medical Group, Ciudad Autonoma de Buenos Aires, Argentina Fundacion Huesped, Ciudad Autonoma De Buenos Aire, Argentina Hospital de Ninos de Cordoba, Cordoba, Argentina Instituto Medico Platense, La Plata, Argentina Centro de Investigaciones Medicas Mar Del Plata, Mar del Plata, Argentina DIM Clinica Privada, Ramos Mejia, Argentina Hospital del Nino Jesus, San Miguel de Tucuman, Argentina Hospital de Clinicas da Universidade Federal De Minas Geraisnas Gerais, Belo Horizonte, Brazil Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, Brazil L2IP - Instituto de Pesquisas Clinicas, Brasilia, Brazil HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas, Campinas, Brazil Nucleo de Medicina Tropical - Universidade Federal do Ceara, Ceara, Brazil Hospital Sao Jose, Criciuma, Brazil Hospital Pequeno Principe, Curitiba, Brazil Centro Medico Sao Francisco, Curitiba, Brazil Fundacao De Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Brazil Centro de Estudos e Pesquisas em Molestias Infecciosas, Natal, Brazil Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil Hospital das Clinicas FMRP-USP, Ribeirao Preto, Brazil Instituto Nacional de Infectologia Evandro Chagas (INI) - FIOCRUZ, Rio de Janeiro, Brazil Hospital Geral de Nova Iguacu - HGNI DST/AIDS, Rio De Janeiro, Brazil Fundacao Faculdade Regional De Medicina De Sao Jose Do Rio Preto, Sao Jose do Rio Preto, Brazil CMPC - Consultoria Medica e Pesquisa Clinica, Sorocaba, Brazil Hospital Das Clinicas Da Faculdade De Medicina Da Universidade De Sao Paulo, Sao Paulo, Brazil Clinica de la Costa, Barranquilla, Colombia Medplus Medicina Prepagada S.A., Bogota, Colombia Centro de Atencion e Investigacion Medica S.A. - CAIMED, Chia, Colombia Corporacion Clinica Universidad Cooperativa De Colombia Clinica Ucc, Villavicencio, Colombia Sri ramchandra Medical College & Research Institute, Chennai, India JSS Hospital, Mysore, India Supe Heart And Diabetes Hospital and Research Center, Nashik, India D.Y.Patil Medical College, Pune, India BAPS Pramukhswami Hospital, Surat, India Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico Instituto Nacional de Pediatria, Ciudad de Mexico, Mexico CAIMED Investigacion en salud S.A de C.V., Ciudad de Mexico, Mexico Hospital Infantil de Mexico Federico Gomez, Ciudad De Mexico, Mexico Hospital General Dr. Manuel Gea Gonzalez, Ciudad de Mexico, Mexico Instituto Nacional de Salud Publica, Cuernavaca, Mexico Unidad Medicina Familiar 52 IMSS, Estado de Mexico, Mexico Kohler & Milstein Research SA de CV, Merida, Mexico Hospital Universitario 'Dr. Jose Eleuterio Gonzalez', Monterrey, Mexico Family Clinical Research Unit FAM-CRU, Cape Town, South Africa Ndlovu Elandsdoorn Site, Dennilton, South Africa Perinatal HIV Research Unit, Guateng Province, South Africa Shandukani Research Centre, Johannesburg, South Africa PHOENIX PHARMA (Pty) Ltd, Port Elizabeth, South Africa Setshaba Research Centre, Soshanguve, South Africa Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, South Africa University of Witwatersrand - Helen Joseph Hospital - Themba Lethu Hiv Research Centre, Westdene Johannesburg Gauteng, South Africa Siriraj Hospital, Bangkok, Thailand Research Institute for Health Sciences, Chiang Mai, Thailand Srinagarind Hospital, Khon Kaen, Thailand Faculty of Medicine, Thammasat University, Pathumthani, Thailand Faculty of Medicine Chulalongkorn University, Pathumwan, Thailand |
| 2356 | Recruiting | A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults | Healthy | Biological: Ad26.COV2.S | Phase 3 | Janssen Vaccines & Prevention B.V. | INDUSTRY | 1590 | All | 18 Years ~ 55 Years | Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States Anaheim Clinical Trials, LLC, Anaheim, California, United States Ark Clinical Research, Long Beach, California, United States Paradigm Clinical Research Centers, Inc., Redding, California, United States California Research Foundation, San Diego, California, United States Wr-McCr, Llc, San Diego, California, United States Ark Clinical Research, Tustin, California, United States Velocity Clinical Research, Hallandale Beach, Hallandale Beach, Florida, United States Health Awareness inc., Jupiter, Florida, United States Meridien Research, Maitland, Florida, United States Floridian Research Institute, Miami, Florida, United States Medpharmics, LLC, Metairie, Louisiana, United States Synexus Clinical Research US, Inc, Saint Louis, Missouri, United States Clinical Research Center of Nevada, Las Vegas, Nevada, United States Rochester Clinical Research, Inc, Rochester, New York, United States Wake Research Associates, Raleigh, North Carolina, United States Trial Management Associates, LLC, Wilmington, North Carolina, United States Tekton Research Inc., Yukon, Oklahoma, United States Coastal Carolina Research Center, North Charleston, South Carolina, United States Ventavia Research Group, LLC, Keller, Texas, United States Research Your Health, Plano, Texas, United States Clinical Research Partners, LLC, Richmond, Virginia, United States Hospital de Clinicas da Universidade Federal De Minas Geraisnas Gerais, Belo Horizonte, Brazil Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, Brazil UFRR - Universidade Federal de Roraima, Boa Vista, Brazil HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas, Campinas, Brazil Nucleo de Medicina Tropical - Universidade Federal do Ceara, Ceara, Brazil Hospital Sao Jose, Criciuma, Brazil Centro de Estudos e Pesquisas em Molestias Infecciosas, Natal, Brazil Hospital Das Clinicas Da Faculdade de Medicina de Ribeirao Preto, Riberao Preto, Brazil Instituto Nacional de Infectologia Evandro Chagas (INI) - FIOCRUZ, Rio de Janeiro, Brazil Hospital Geral de Nova Iguacu - HGNI DST/AIDS, Rio De Janeiro, Brazil Centro de Referencia E Treinamento Dst/Aids, Sao Paulo, Brazil CPQuali Pesquisa Clinica LTDA ME, Sao Paulo, Brazil Klinische Forschung Berlin-Mitte GmbH, Berlin, Germany Clinical Research HamburggmbH, Hamburg, Germany Klinische Forschung Hannover-Mitte GmbH, Hannover, Germany Synexus Clinical Research GmbH, Leipzig, Germany Universitaetsmedizin Rostock, Rostock, Germany Centrum Medyczne PRATIA Bydgoszcz, Bydgoszcz, Poland Uniwersyteckie Centrum Kliniczne, Osrodek Badan Klinicznych Wczesnych Faz, Gdansk, Poland Neutrum Lekarze M.Hlebowicz i Partnerzy spolka partnerska, Gdansk, Poland Gdanskie Centrum Zdrowia, Gdansk, Poland Centrum Medyczne Medyk, Rzeszow, Poland Centrum Medyczne Pratia Poznan, Skorzewo, Poland Nasz Lekarz, Nzoz, Praktyka Grupowa Lekarzy Rodzinnych z Przychodn, Torun, Poland Szpital im. Swietej Jadwigi Slaskiej, Oddział Pediatryczny z Pododdziałem Niemowl?cym, Trzebnica, Poland SP ZOZ Wroclawskie Centrum Zdrowia, Wroclaw, Poland Centrum Badan Klinicznych, Osrodek Badan Wczesnej Fazy, Wroclaw, Poland Synexus Helderberg Clinical Research Centre, Cape Town, South Africa Ndlovu Elandsdoorn Site, Dennilton, South Africa Queenswood Clinical Trial Centre, Gauteng, South Africa Centre for the AIDS Programme of Research in South Africa, KwaZulu-Natal, South Africa Stanza Clinical Research Centre : Mamelodi, Mamelodi East, South Africa PHOENIX PHARMA (Pty) Ltd, Port Elizabeth, South Africa Setshaba Research Centre, Soshanguve, South Africa |
| 2355 | Recruiting | A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults | Immunocompromised | Drug: casirivimab+imdevimab Drug: Placebo |
Phase 3 | Regeneron Pharmaceuticals | INDUSTRY | 8752 | All | 12 Years | Central Alabama Research, Birmingham, Alabama, United States Regeneron Study Site, Long Beach, California, United States Regeneron Study Site, Los Angeles, California, United States Cedars-Sinai Medical Center, Los Angeles, California, United States Stanford University, Palo Alto, California, United States University of California, Sacramento, California, United States Regeneron Study Site, Stanford, California, United States James R Berenson MD Inc., West Hollywood, California, United States University Of Colorado, Aurora, Colorado, United States Regeneron Study Site, North Haven, Connecticut, United States Regeneron Study Site, Washington, District of Columbia, United States Midway Immunology and Research Center, Fort Pierce, Florida, United States Elixia COVID-19, Hollywood, Florida, United States AppleMed Research Group, LLC, Miami, Florida, United States De La Cruz Research Center, LLC, Miami, Florida, United States University of South Florida, Tampa, Florida, United States Regeneron Study Site, Atlanta, Georgia, United States Regeneron Study Site, Marietta, Georgia, United States Great Lakes Clinical Trials - Ravenswood, Chicago, Illinois, United States Regeneron Study Site, Iowa City, Iowa, United States Johns Hopkins Hospital, Baltimore, Maryland, United States Regeneron Study Site, Boston, Massachusetts, United States Regeneron Study Site, Boston, Massachusetts, United States Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States Regeneron Study Site, Ann Arbor, Michigan, United States University of Nebraska Medical Center, Omaha, Nebraska, United States Holy Name, Teaneck, New Jersey, United States Montefiore Medical Center, Bronx, New York, United States Icahn School of Medicine at Mount Sinai, New York, New York, United States Regeneron Study Site, New York, New York, United States Memorial Sloan Kettering Cancer Center, New York, New York, United States Regeneron Study Site 2, New York, New York, United States Regeneron Study Site, Rochester, New York, United States Regeneron Study Site, Syracuse, New York, United States Burke Primary Care, Morganton, North Carolina, United States Regeneron Study Site, Cleveland, Ohio, United States Miami Valley Hospital, Dayton, Ohio, United States Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States Penn Prevention Clinical Research Site, Philadelphia, Pennsylvania, United States Temple University, Philadelphia, Pennsylvania, United States Regeneron Study Site, Providence, Rhode Island, United States PharmaTex Research, LLC, Amarillo, Texas, United States Therapeutic Concepts, PA, Houston, Texas, United States Houston Methodist Hospital, Houston, Texas, United States MD Anderson Cancer Center, Houston, Texas, United States Synergy Group Medical,LLC, Houston, Texas, United States Regeneron Study Site, Richmond, Virginia, United States Fred Hutchinson Cancer Research Center, Seattle, Washington, United States Regeneron Study Site, Seattle, Washington, United States University of Wisconsin - Madison, Madison, Wisconsin, United States Regeneron Study Site, Cuauhtemoc, Distrito Federal, Mexico |
